Searchable abstracts of presentations at key conferences in endocrinology

ea0015oc33 | Thyroid | SFEBES2008

Effect of thyroid status on the skeleton in post-menopausal women: the OPUS study

Murphy Elaine , Gluer Claus C , Reid David M , Felsenberg Dieter , Roux Christian , Eastell Richard , Williams Graham R

OPUS is a population-based prospective cohort study of post-menopausal women from five European cities. We investigated whether TSH, fT4 and fT3 are associated with fracture risk, bone mineral density (BMD) at hip and spine, bone formation (osteocalcin, procollagen type 1 N-terminal propeptide), bone resorption (N- and C-telopeptides of type 1 collagen, NTX, CTX), pulse rate, grip strength and balance. Vertebral fractures were determined at baseline and 6 years follow-up. Usin...

ea0013oc8 | Clinical and translational endocrinology | SFEBES2007

Effect of once-yearly infusion of Zoledronic acid 5 mg in postmenopausal women with osteoporosis

Eastell Richard , Black Dennis , Cauley Jane , Cosman Felicia , Cummings Steve , Delmas Pierre , Eriksen Erik Fink , Fraser William , Hue Trisha , Lakatos Peter , Leung Ping-Chung , Man Zulema , McLellan Alastair , Mesenbrink Peter , Reid David M , Reid Ian , Boonen Steven

Objectives and methods: The HORIZON-PFT is a multinational, 3-year, randomized, double-blind, placebo-controlled trial evaluating the potential of once-yearly zoledronic acid (ZOL) 5 mg, infused over 15 minutes, to decrease risk of fracture in 7736 postmenopausal osteoporotic women 65–89 years of age.Results: Treatment with ZOL 5 mg resulted in significant relative risk reductions in morphometric vertebral fracture of 70% vs PBO (3.8% vs 12.8%; 95% ...